Surgery

You are here

Clinical Trials

The Department of Surgery doesn’t just excel in the operating room. Through our extensive and innovative research programs, we are also focused on the development of new techniques and therapies that promote better outcomes and improve the quality of life for patients following surgery. 

As part of that goal, the department’s surgeons are involved in groundbreaking clinical trials. In addition to their research value, clinical trials may also give patients access to new treatments that are not available anywhere else.

Learn more about our current clinical trials below or visit the Joint Clinical Trials Office at Weill Cornell Medicine and NewYork-Presbyterian.

The purpose of this study is to learn more about a patient’s transplant and related complications. We will develop tests for assessing the status of the kidney transplant, as well as any potential complications.

The transition from the hospital back home can be a difficult time for patients. About 1 in 3 patients will suffer worsening quality of life or readmission to the hospital within the first 30 days. 

Key Inclusion / Exclusion Criteria:
  • At least 70 years of age
  • Primary discharge diagnosis related to cardiovascular disease or heart failure 
  • Being discharged to an independent living facility
  • Detailed study eligibility to be reviewed with study team

This clinical trial is for men and women who have cirrhosis of the liver and have achieved a sustained virologic response (SVR) to a sofosbuvir based regimen without interferon after participating in a Gilead Sciences study for chronic Hepatitis C infection.

Key Inclusion / Exclusion Criteria:
  • Men and women who are 18 years of age and older
  • Participated in a previous Gilead Science study for HCV
  • Have cirrhosis of the liver
  • Achieved SVR to a sofosbuvir regimen without interferon
  • Detailed eligibility reviewed when you contact the study team

This study will follow patients seen in the in/outpatient setting at Weill Cornell Medical College with current or past diagnosis of heart failure (HF) and pulmonary hypertension (PH). The study has three specific aims:

Key Inclusion / Exclusion Criteria:

Inclusion criteria:

  • All inpatients and outpatients at Weill Cornell Medical Center whose principal or consulting attending physician is Dr. Sobol or Dr. Horn (co-investigator on this study) who have been diagnosed with HF (either with preserved or depressed ejection fraction) and/or pulmonary hypertension will be eligible to participate.

Exclusion criteria:

  • Patient inability to consent or refusal to participate

This clinical trial is to evaluate the safety and efficacy of an investigational drug named emricasan (IDN-6556) in men and women who are 18 years or older who have been diagnosed with non-alcoholic steatohepatitis (NASH) fibrosis. 

Key Inclusion / Exclusion Criteria:

- Men and women who are 18 years of age and older. 

- Have Non-alcoholic Steatohepatitis (NASH) Fibrosis 

- Detailed eligibility reviewed when you contact the study team. 

This clinical trial is to evaluate the safety and efficacy of an investigational drug named emricasan (IDN-6556) in men and women who are 18 years or older who have been diagnosed with decompensated non-alcoholic steatohepatitis (NASH) cirrhosis. 

Key Inclusion / Exclusion Criteria:

   1. Men and women who are 18 years of age and older. 
   2. Have decompensated Non-alcoholic Steatohepatitis (NASH) cirrhosis. 
   3. Detailed eligibility reviewed when contacting the study team. 

This clinical trial is to evaluate an experimental (investigational) drug in men or women who have been diagnosed and recently hospitalized with decompensated liver cirrhosis and ascites. 
    

Key Inclusion / Exclusion Criteria:

- Men and women who are 18 years of age and older. 
- Individuals with decompensated cirrhosis and ascites. 
- Detailed eligibility reviewed when contacting the study team. 

Over the last two decades, mechanical circulatory support devices (MCSDs) have been developed to augment or supplant failing myocardial performance.

Key Inclusion / Exclusion Criteria:

Inclusion criteria:

  • Patients with an FDA-approved MCSD implanted on or after March 1, 2006. Every patient who has signed consent and has received an eligible MCSD at a participating center will be enrolled, regardless of the reason of implantation (i.e., bridge-to-recovery, bridge-to-alternative bridge, bridge-to-clinical improvement for transplant eligibility, bridge-to-transplant, destination therapy)
  • Eligible devices include all of the following:
    • approved devices for any indications except through a registered clinical trial
    • INTERMACS-linked trial of investigational device or approved device for investigational indications, for which data will be entered via the INTERMACS framework
    • external trial of investigational device or approved device for investigational indications, for which data will be collected by an external group
    • compassionate use of investigational devices or approved devices outside of approved indications or clinical trials

Exlcusion criteria:

  • Currently incarcerated

This clinical trial is for men and women who have been diagnosed with compensated cirrhosis as a result of non-alcoholic steatohepatitis (NASH).

Key Inclusion / Exclusion Criteria:
  • Men and women who are 18 years of age and older. 
  • Must be diagnosed with NASH. 
  • Detailed eligibility reviewed when you contact the study team. 

Find a Physician

Surgical Services
Weill Cornell Medicine Surgery

Visit our Surgery YouTube channel to view our video library.